The Genomic Atlas of Breast Cancer — the non-coding theme

Update News

  • GABC update 2020.06.15
  • GABC update 2019.03.20
  • GABC online 2018.08.09
  • Data collection 2018.04.09

About Us

  • Steven Xi Chen:
    steven.chen@miami.edu
  • Yunpeng Zhang:
    YXZ1418@med.miami.edu
  • Peng Wang:
    wpgqy@163.com
  • Shangwei Ning:
    ningsw@ems.hrbmu.edu.cn
  • Xia Li:
    lixia@hrbmu.edu.cn

Detail


Chr chr1
start 3735601
end 3747336
lncRNA name TP73-AS1
entrez id 57212
hgnc id HGNC:29052
ensg id ENSG00000227372
refseq id NR_033708
methods qPCR, Luciferase reporter assay, Western blot
regulated up-regulated
function description TP73-AS1 was specifically upregulated in BC tissues and BC cell lines and was correlated to a poorer prognosis in patients with BC. TP73-AS1 could regulate miR-200a through direct targeting. Moreover, TP73-AS1 might compete with TFAM for miR-200a binding thus to promote TFAM expression.TP73-AS1 promoted BC cell proliferation through acting as a competing endogenous RNA (ceRNA) by sponging miR-200a. High TP73-AS1 expression in BC was related with poorer clinicopathological parameters and shorter overall survival.
pubmed id 28639399
year 2017
title TP73-AS1 promotes breast cancer cell proliferation through miR-200a-mediated TFAM inhibition.
drug X
circulating X
survival V

CopyRight © University of Miami, USA; Harbin Medical University, China